Review article · 2026 · Open access

Advancing Evidence Generation in Small, Diverse, Understudied Population

Amitava Mitra, Anne‐Gaëlle Dosne, Douglas Steinbach, Hannah M. Jones, John T. Mondick, Rajesh Krishna

Clinical Pharmacology & Therapeutics · Published 31 October 2026 · DOI 10.1002/cpt.70548

Open PDFView at the publisherCite this paper

In brief

“Advancing Evidence Generation in Small, Diverse, Understudied Population” is a 2026 review article by Amitava Mitra and 5 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 17 November 2026. It is open access: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
0
References
79
Authors
6

Abstract

Many clinically important patient groups remain systematically underrepresented in drug development. Among these are patients with severe or time-varying organ dysfunction, pregnant and lactating women, children with ultrarare diseases, and people from socioeconomically or geographically underserved communities. Traditional clinical trials frequently exclude such groups. Little direct evidence is generated as a result, leaving benefit-risk and dosing decisions uncertain and trial findings poorly generalizable to the patients who will ultimately receive the drug. No single method closes this gap. This review argues that progress instead comes from integration, combining model-informed drug development, registries and real-world data, external and virtual controls, Bayesian borrowing, and patient-centric trial designs into a coherent totality-of-evidence package. These tools are maturing from a role that supplements clinical data toward one that can, in defined settings, partially replace it. The appropriate approach may differ by population. For example, (1) mechanistic modeling and exposure prediction for organ replacement therapy/changing organ function or from the altered maternal-fetal-infant physiology that makes prospective studies impractical; (2) registry-based external controls and natural history data where patients are too few to randomize; and (3) decentralized, partnership-driven designs to reach populations that structural barriers would otherwise exclude. Three case studies (dose justification across hepatic and renal impairment, evidence generation in women of childbearing potential with chronic autoimmune disease, and a registry-anchored ultrarare pediatric program) illustrated these approaches. Mapped to evolving regulatory frameworks, these strategies can deliver population-appropriate dosing at approval rather than through postmarketing commitments, accelerating equitable access to safe and effective therapies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mitra, A., Dosne, A., Steinbach, D., Jones, H. M., Mondick, J. T., & Krishna, R. (2026). Advancing Evidence Generation in Small, Diverse, Understudied Population. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70548

MLA 9

Mitra, Amitava, et al. “Advancing Evidence Generation in Small, Diverse, Understudied Population.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70548.

Chicago

Mitra, Amitava, Anne‐Gaëlle Dosne, Douglas Steinbach, Hannah M. Jones, John T. Mondick, and Rajesh Krishna. 2026. “Advancing Evidence Generation in Small, Diverse, Understudied Population.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70548.

Harvard

Mitra, A. et al. (2026) ‘Advancing Evidence Generation in Small, Diverse, Understudied Population’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70548.

IEEE

A. Mitra, A. Dosne, D. Steinbach, H. M. Jones, J. T. Mondick, and R. Krishna, “Advancing Evidence Generation in Small, Diverse, Understudied Population,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70548.

BibTeX

@article{mitra2026advancing,
  title     = {{Advancing Evidence Generation in Small, Diverse, Understudied Population}},
  author    = {Mitra, Amitava and Dosne, Anne‐Gaëlle and Steinbach, Douglas and Jones, Hannah M. and Mondick, John T. and Krishna, Rajesh},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70548},
  url       = {https://doi.org/10.1002/cpt.70548}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials

  • model-informed drug development
  • real-world data
  • registry
  • external control
  • virtual control
  • organ dysfunction
  • liver dysfunction
  • renal dysfunction

Work with this paper

Most-cited papers in Mathematics

All highly cited Mathematics papers

Questions about this paper

How do I cite this paper in APA style?

Mitra, A., Dosne, A., Steinbach, D., Jones, H. M., Mondick, J. T., & Krishna, R. (2026). Advancing Evidence Generation in Small, Diverse, Understudied Population. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70548

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Amitava Mitra, Anne‐Gaëlle Dosne, Douglas Steinbach, Hannah M. Jones, John T. Mondick, Rajesh Krishna.

What is the DOI of this paper?

10.1002/cpt.70548, permanently at https://doi.org/10.1002/cpt.70548. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.